Aduro Biotech Inc. (NASDAQ:ADRO) traded up 2.3% during trading on Wednesday . The stock traded as high as $15.77 and last traded at $15.61, with a volume of 59,074 shares changing hands. The stock had previously closed at $15.26.

Several equities research analysts have commented on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 price objective on shares of Aduro Biotech in a report on Friday, August 5th. FBR & Co reaffirmed a “buy” rating on shares of Aduro Biotech in a report on Friday, April 29th. Zacks Investment Research downgraded shares of Aduro Biotech from a “hold” rating to a “sell” rating in a report on Monday, July 18th. Roth Capital reaffirmed a “buy” rating and set a $22.00 price objective on shares of Aduro Biotech in a report on Monday, July 11th. Finally, Leerink Swann reissued a “buy” rating and issued a $48.00 price target on shares of Aduro Biotech in a report on Thursday, May 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $22.00.

The company’s market cap is $891.66 million. The firm has a 50-day moving average of $14.38 and a 200-day moving average of $13.22.

Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.18) by $0.21. The business earned $39 million during the quarter, compared to the consensus estimate of $25.24 million. The company’s revenue for the quarter was up 306.3% on a year-over-year basis. On average, equities analysts anticipate that Aduro Biotech Inc. will post ($1.15) EPS for the current year.

In related news, insider Thomas W. Dubensky sold 25,000 shares of Aduro Biotech stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $15.18, for a total value of $379,500.00. Following the completion of the sale, the insider now directly owns 12,500 shares in the company, valued at approximately $189,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

A hedge fund recently raised its stake in Aduro Biotech stock. Jennison Associates LLC raised its stake in Aduro Biotech Inc. (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned 1.35% of Aduro Biotech worth $24,069,000 at the end of the most recent quarter.

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.